Tigemonam activity against clinical isolates of Enterobacteriaceae and Enterobacteriaceae with known mechanisms of resistance to beta-lactam antibiotics

J Antimicrob Chemother. 1989 Aug;24(2):173-81. doi: 10.1093/jac/24.2.173.

Abstract

Tigemonam, a new oral monobactam, was at least as active as aztreonam or carumonam against clinical isolates of Enterobacteriaceae (MIC90:0.06-16 mg/l). Tigemonam was very stable in the presence of classical plasmid mediated beta-lactamases but its MICs were increased (4-256 mg/l) in the presence of new broad-spectrum plasmid mediated beta-lactamases (either TEM of SHV derivatives). Increased MICs (0.25-8 mg/l) were also observed for different isogenic mutants of Enterobacteriaceae, which either produced high levels of chromosome-encoded cephalosporinases, or had a permeability defect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Microbial
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / isolation & purification
  • Escherichia coli / drug effects
  • Klebsiella / drug effects
  • Microbial Sensitivity Tests
  • Monobactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Monobactams
  • tigemonam